SCHEMBL5154372

SCHEMBL5154372

NC(=O)Nc1c(F)cc(F)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KIF11 P52732 2/20 0.43
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
CES2 O00748 2/20 0.40
CES1 P23141 2/20 0.40
FUCA1 P04066 1/20 0.40
ERN1 O75460 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
IKBKB O14920 1/20 0.37
JAK2 O60674 1/20 0.37
EIF2AK2 P19525 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29344133 0.85 KEAP1 (0.42) ALDH1A1KIF11KMT2AMAPTCES2
SCHEMBL18415476 0.81 CES2 (0.43) ALDH1A1KMT2AMAPTCES2CES1
SCHEMBL11578513 0.81 ALDH1A1 (0.36) ALDH1A1KIF11KMT2AMAPTCES2
SCHEMBL1090853 0.79 ALDH1A1 (0.38) ALDH1A1KIF11KMT2AMEN1IKBKB
SCHEMBL2092769 0.79 RAPGEF4 (0.42) ALDH1A1KMT2AMAPTCES2CES1
SCHEMBL2092767 0.79 CES2 (0.41) ALDH1A1KMT2AMAPTCES2CES1
SCHEMBL15328160 0.78 ALDH1A1 (0.51) ALDH1A1KMT2AMAPTSMN1; SMN2IKBKB
SCHEMBL1440033 0.78 BTK (0.41) ALDH1A1KMT2AMAPTSMN1; SMN2MEN1
SCHEMBL2566903 0.77 FUCA1 (0.43) ALDH1A1KMT2AMAPTCES2CES1
SCHEMBL1440801 0.77 KMT2A (0.55) ALDH1A1KMT2ACES2CES1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295655-A1 BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION Alk-Abelló A/S (DK) 2025-09-25 US disclosed
CN-118027038-A Hydrogen-bond-assisted chiral dicycloimidazole organic micromolecular catalyst and synthesis method thereof 上海交通大学 2024-05-14 CN disclosed
CN-103228633-A Heterocyclic compounds as DGAT1 inhibitors PIRAMAL LIFE SCIENCES LTD 2013-07-31 CN disclosed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP disclosed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295655-A1 BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION BTK, SYK, ABL1 ALDH1A1 4690/4885KIF11 4487/4885KMT2A 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.